FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
In a major regulatory leadership decision, the U.S. Food and Drug Administration (FDA) has appointed Dr. Richard Pazdur, a long-time oncology expert, as the director of its Center for Drug Evaluation and Research (CDER). Pazdur, who has been with the FDA since 1999 and previously led the Oncology Center of Excellence, is known for his regulatory innovation and deep expertise.
His track record includes expediting cancer drug approvals and championing patient-centric regulation. Colleagues and patient advocacy groups have praised his scientific integrity and compassion-driven leadership.
This appointment comes amid a broader shake-up at the FDA, and brings a steady, experienced hand to one of the agency’s most critical divisions — which oversees both prescription and over-the-counter medicines.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
GHKCU 50mg High Purity Peptide Not For Human Use
$78/UNIT FOB
2026-07-16
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
McKinsey Pays to Close a Purdue Liability Chapter
Recommend Reading
-
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
-
EU Authorises Propionic Acid and Its Salts as Feed Additives Until 2035
-
Crude Oil Prices Decline, Local Refinery Gasoline and Diesel Prices Fall in China
-
MTBE Market Trend Shows Significant Decline in China
-
Henkel’s €60 Million Adhesive Technologies Inspiration Center in Shanghai Goes into Operation, Aiming to Build an R&D Hub for Asia-Pacific
-
Breakup! Vland Biotech and Evonik Part Ways as GHS Joint Venture Falls Short of Expectations